c-Jun N-Terminal Kinases (JNKs) in Myocardial and Cerebral Ischemia/Reperfusion Injury / M. V. Shvedova, Ya. J. Anfinogenova, E. N. Atochina [et al.]

Уровень набора: Frontiers in PharmacologyАльтернативный автор-лицо: Shvedova, M. V., врач-хирург, младший научный сотрудник Томского политехнического университета, 1989-, Mariya Vitaljevna;Anfinogenova, Ya. J., Linguist, Lecturer of Tomsk Polytechnic University, Doctor of medical sciences, 1970-, Yana Jonovna;Atochina, E. N., biophysicist, Director of RASA Center in Tomsk of Tomsk Polytechnic University, 1963-, Elena Nikolaevna;Shchepyotkin, I. A., doctor-biophysicist, leading researcher of Tomsk Polytechnic University, candidate of medical science, 1962-, Igor Aleksandrovich;Atochin, D. N., neuroscientist, The Head of the Laboratory of Tomsk Polytechnic University, 1960-, Dmitry NikolaevichКоллективный автор (вторичный): Национальный исследовательский Томский политехнический университет, Инженерная школа новых производственных технологий, Научно-образовательный центр Н. М. Кижнера;Национальный исследовательский Томский политехнический университет, Инженерная школа природных ресурсов, Отделение химической инженерииЯзык: английский.Страна: .Резюме или реферат: In this article, we review the literature regarding the role of c-Jun N-terminal kinases(JNKs) in cerebral and myocardial ischemia/reperfusion injury. Numerous studiesdemonstrate that JNK-mediated signaling pathways play an essential role in cerebraland myocardial ischemia/reperfusion injury. JNK-associated mechanisms are involved inpreconditioning and post-conditioning of the heart and the brain. The literature and ourown studies suggest that JNK inhibitors may exert cardioprotective and neuroprotectiveproperties. The effects of modulating the JNK-depending pathways in the brain andthe heart are reviewed. Cardioprotective and neuroprotective mechanisms of JNKinhibitors are discussed in detail including synthetic small molecule inhibitors (AS601245,SP600125, IQ-1S, and SR-3306), ion channel inhibitor GsMTx4, JNK-interactingproteins, inhibitors of mixed-lineage kinase (MLK) and MLK-interacting proteins, inhibitorsof glutamate receptors, nitric oxide (NO) donors, and anesthetics. The role of JNKs inischemia/reperfusion injury of the heart in diabetes mellitus is discussed in the contextof comorbidities. According to reviewed literature, JNKs represent promising therapeutictargets for protection of the brain and the heart against ischemic stroke and myocardialinfarction, respectively. However, different members of the JNK family exert diversephysiological properties which may not allow for systemic administration of non-specificJNK inhibitors for therapeutic purposes. Currently available candidate JNK inhibitors withhigh therapeutic potential are identified. The further search for selective JNK3 inhibitorsremains an important task..Тематика: электронный ресурс | труды учёных ТПУ | brain | heart | c-Jun-N-terminal kinase | JNK inhibitor | ischemia/reperfusion injury | stroke | мозг | сердце | ингибиторы | ишемия Ресурсы он-лайн:Щелкните здесь для доступа в онлайн | Щелкните здесь для доступа в онлайн
Тэги из этой библиотеки: Нет тэгов из этой библиотеки для этого заглавия. Авторизуйтесь, чтобы добавить теги.
Оценка
    Средний рейтинг: 0.0 (0 голосов)
Нет реальных экземпляров для этой записи

Title screen

In this article, we review the literature regarding the role of c-Jun N-terminal kinases(JNKs) in cerebral and myocardial ischemia/reperfusion injury. Numerous studiesdemonstrate that JNK-mediated signaling pathways play an essential role in cerebraland myocardial ischemia/reperfusion injury. JNK-associated mechanisms are involved inpreconditioning and post-conditioning of the heart and the brain. The literature and ourown studies suggest that JNK inhibitors may exert cardioprotective and neuroprotectiveproperties. The effects of modulating the JNK-depending pathways in the brain andthe heart are reviewed. Cardioprotective and neuroprotective mechanisms of JNKinhibitors are discussed in detail including synthetic small molecule inhibitors (AS601245,SP600125, IQ-1S, and SR-3306), ion channel inhibitor GsMTx4, JNK-interactingproteins, inhibitors of mixed-lineage kinase (MLK) and MLK-interacting proteins, inhibitorsof glutamate receptors, nitric oxide (NO) donors, and anesthetics. The role of JNKs inischemia/reperfusion injury of the heart in diabetes mellitus is discussed in the contextof comorbidities. According to reviewed literature, JNKs represent promising therapeutictargets for protection of the brain and the heart against ischemic stroke and myocardialinfarction, respectively. However, different members of the JNK family exert diversephysiological properties which may not allow for systemic administration of non-specificJNK inhibitors for therapeutic purposes. Currently available candidate JNK inhibitors withhigh therapeutic potential are identified. The further search for selective JNK3 inhibitorsremains an important task.

Для данного заглавия нет комментариев.

оставить комментарий.